Read & Download your Issue of Wednesday – January 13 FNN News

No clinical benefit in mortality associated with hydroxychloroquine treatment in patients with COVID-19

• The use of hydroxychloroquine (HCQ), with or without concurrent administration of azithromycin (AZM), for treatment of COVID-19 has received considerable attention.
• The purpose of this study was to determine whether HCQ administration is associated with improved mortality in COVID-19 patients.
• In this retrospective analysis, they found that there was no benefit of administration of HCQ on mortality in COVID-19 patients.
• These results support recent changes to clinical trials that discourage the use of HCQ in COVID-19 patients.

Source: ScienceDirect

mRNA Vaccines to Prevent COVID-19 Disease and Reported Allergic Reactions: Current Evidence and Approach

• The recent Food and Drug Administration (FDA) approval of two highly effective COVID-19 vaccines from Pfizer-BioNtech and Moderna has brought hope to millions.
• The FDA Emergency Use Authorization guidance for both vaccines is to not administer the vaccine to individuals with known history of a severe allergic reaction (e.g., anaphylaxis) to any component of the COVID-19 vaccine.
• This review summarizes vaccine allergy epidemiology and proposes risk stratification schema.

Source: ScienceDirect

Effect of COVID-19 on pre-existing liver disease: What Hepatologist should know?

• COVID-19 is characterized by predominant respiratory and gastrointestinal symptoms.
• Liver enzymes derangement is seen in 15-55% of the patients.
• Advanced age, hypertension, diabetes, obesity, malignancy and, cardiovascular disease predispose them to severe disease and the need for hospitalization.
• Data on preexisting liver disease in patients with COVID -19 is limited and most studies had only 3-8% of these patients.
• This short review assessed the effect of COVID-19 in patients with pre-existing liver disease.

Source: ScienceDirect

Clinically distinct COVID-19 cases share notably similar immune response progression: A follow-up analysis

• Inflammatory responses to the novel coronavirus SARS-CoV-2, which causes COVID-19, range from asymptomatic to severe.
• Here they present a follow-up analysis of a longitudinal study characterizing COVID-19 immune responses from a father and son with distinctly different clinical courses.
• This study provides insight into the immune responses of likely millions of people with extremely mild symptoms who may not be aware of their infection with SARS-CoV-2 and implies a potential for long-lasting consequences that could contribute to reinfection risk.

Source: ScienceDirect

The find of COVID-19 vaccine: Challenges and opportunities

• Severe acute respiratory syndrome coronavirus (SARS-CoV-2) is the first alarming pandemic of the third millennium.
• The current review is redirected to the scientific community to owe comprehensive visualization about SARS-CoV-2 to tackle the current pandemic.
• As systematically shown through the current review, it indexes unmet medical problem of COVID-19 in view of public health and vaccination discovery for the infectious SARS-CoV-2

Source: ScienceDirect

Incidence of thrombotic complications and overall survival in hospitalized patients with COVID-19 in the second and first wave

• In the first wave, thrombotic complications were common in COVID-19 patients.
• It is unknown whether state-of-the-art treatment has resulted in less thrombotic complications in the second wave.
• In total 947 patients with COVID-19 were included in this analysis, of whom 358 patients were admitted to the ICU; 144 patients died (15%).
• The adjusted cumulative incidence of all thrombotic complications after 10, 20 and 30 days was 12%

Source: ScienceDirect

• Read more from FADIC Blog, with many articles with evidence based articles.
• Learn More Through FADIC® – Online Programs & Mini-Courses.
• Listen Now to FADIC Podcast focusing on varieties of pharmacist perspectives in specialties.
• Read More Now about FADIC Pharmacy Events to get more Experience.

Course Copyrights:

All Courses is meant for SINGLE user use only.
If more than one person acceced this course, they will be BLOCKED Forever.

Why FADIC 2021 Clinical Research E-News ?

• It helps to keep up with the literature!
• Provide you with the Updated with the latest in your clinical practice. Wherever you are, and Whenever you need!
• Help you to share in the advance in clinical career. In addition to adding an impressive image to the pharmacists all-around!

Subscribe to FADIC 2021 Clinical Research FNN E-News, for a publication of News

Read & Download FNN Issue 8 of April 2020 FNN News